Netherlands' Qiagen Q3 sales, adjusted EPS top outlook; suspends 2026 guidance

Overview

• Netherlands molecular diagnostics firm's Q3 net sales rose 3% yr/yr, exceeding company outlook

• Adjusted diluted EPS for Q3 rose to $0.65, above company outlook

• Company suspended 2026 financial guidance due to pending EQT Private Equity transaction

Outlook

• Qiagen has suspended its 2026 outlook due to the pending EQT Private Equity transaction

Result Drivers

• CONSUMABLES GROWTH - Consumables and related revenues rose 3% CER and made up 91% of sales, while instrument sales rose 1% CER

• MARGIN IMPROVEMENT - Higher-margin consumables and efficiency gains contributed to increased adjusted operating income margin

• GROWTH PILLARS - Sales from QIAGEN's growth pillars rose 7% CER to $415 mln, partly offset by a 7% CER decline in the rest of the portfolio

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for QIAGEN N.V. is €44.61, about 1.4% below its November 4 closing price of €45.23

• The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 16 three months ago

Reuters Recommended Reads

• Nov 3 - Netherlands' Philips slightly misses Q3 revenue estimates, maintains 2026 forecast

• Nov 3 - Life sciences tech firm Waters' Q3 revenue, adjusted EPS beat estimates

• Nov 3 - Revvity Q3 revenue beats estimates, raises FY guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)